Last Updated : November 14, 2024
Details
FilesGeneric Name:
faricimab
Project Status:
Active
Therapeutic Area:
Retinal vein occlusion
Manufacturer:
Hoffmann-La Roche Limited
Call for patient/clinician input open:
Brand Name:
Vabysmo
Project Line:
Reimbursement Review
Project Number:
SR0832-000
Call for patient/clinician input closed:
NOC Status at Filing:
Post NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
For the treatment of macular edema secondary to retinal vein occlusion (RVO).
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
For the treatment of macular edema secondary to retinal vein occlusion (RVO).
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
| Call for patient/clinician input open | 22-Apr-24 |
|---|---|
| Call for patient/clinician input closed | 17-Jun-24 |
| Submission received | 31-Jul-24 |
| Submission accepted | - |
| Review initiated | 16-Aug-24 |
| Draft CADTH review report(s) provided to sponsor for comment | 01-Nov-24 |
| Deadline for sponsors comments | 13-Nov-24 |
| CADTH review report(s) and responses to comments provided to sponsor | 06-Dec-24 |
| Expert committee meeting (initial) | 18-Dec-24 |
| Draft recommendation issued to sponsor | January 07, 2025 To January 09, 2025 |
| Draft recommendation posted for stakeholder feedback | 16-Jan-25 |
| End of feedback period | 31-Jan-25 |
Files
Last Updated : November 14, 2024